EXTON, Pa.--(BUSINESS WIRE)--Aug. 30, 2006--Adolor Corporation (Nasdaq: ADLR) announced today that it has initiated a Phase 1 clinical trial of ADL5859, a novel, orally bioavailable Delta opioid receptor agonist. The Phase 1 study is designed to investigate the safety, tolerability and pharmacokinetics of a single dose of ADL5859 in healthy volunteers. As a next step in the development, the company plans to conduct a multi-dose safety study.
